Skip Navigation


Annals of Oncology Advance Access originally published online on April 10, 2007
Annals of Oncology 2007 18(6):1071-1079; doi:10.1093/annonc/mdm090
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/6/1071    most recent
mdm090v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bartlett, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bartlett, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

hematologic malignancies

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804

NL Bartlett1, D Niedzwiecki2, JL Johnson2, JW Friedberg3, KB Johnson4, K van Besien5, AD Zelenetz6, BD Cheson7, GP Canellos3 For the Cancer Leukemia Group B

1 Siteman Cancer Center, Washington University School of Medicine, St Louis, MO
2 CALGB Statistical Center, Duke University Medical Center, Durham, NC
3 Dana Farber-Partners, Boston, MA
4 University of California at San Diego, San Diego, CA
5 University of Chicago, Chicago, IL
6 Memorial Sloan-Kettering Cancer Center, New York, NY
7 Georgetown University Medical Center, Washington, DC, USA

* Correspondence to: Dr Nancy L. Bartlett, Siteman Cancer Center, Washington University School of Medicine, 660 S Euclid, Box 8056, St Louis, MO 63110, USA. Tel: +314-362-5654; Fax: +314-747-5123; E-mail: nbartlet{at}im.wustl.edu

Background: Because of high single-agent activity and modest toxicity, we hypothesized the combination of gemcitabine (G), vinorelbine (V), and pegylated liposomal doxorubicin (D) would be an effective salvage therapy for Hodgkin's lymphoma (HL).

Patients and methods: A total of 91 patients participated. GVD was administered on days 1 and 8 every 21 days at doses of G 1000 mg/m2, V 20 mg/m2, and D 15 mg/m2 for transplant-naive patients, and G 800 mg/m2, V 15 mg/m2, and D 10 mg/m2 for post-transplant patients.

Results: The dose-limiting toxicity was mucositis for the transplant-naive patients and febrile neutropenia for post-transplant patients. The overall response rate (RR) for all patients was 70% [95% confidence interval (CI) 59.8, 79.7], with 19% complete remissions. The 4-year event-free and overall survival rates in transplant-naive patients treated with GVD followed by autologous transplant were 52% (95% CI 0.34, 0.68) and 70% (95% CI 0.49, 0.84), and in the patients in whom prior transplant failed, these were 10% (95% CI 0.03, 0.22) and 34% (95% CI 0.17, 0.52), respectively.

Conclusions: GVD is a well-tolerated, active regimen for relapsed HL with results similar to those reported for more toxic regimens. High RRs in patients in whom prior transplant failed confirms this regimen's activity even in heavily pretreated patients.

Key words: gemcitabine, Hodgkin's lymphoma, liposomal doxorubicin, recurrent, salvage therapy, vinorelbine

N. L. Bartlett designed research, performed research, analyzed data, and wrote the paper; D. Niedzwiecki designed research and analyzed data; J. L. Johnson designed research, collected data, and analyzed data; J. W. Friedberg treated significant proportion of patients on trial and edited the paper; K. B. Johnson treated significant proportion of patients on trial and edited the paper; K. van Besien treated significant proportion of patients on trial and edited the paper; A. D. Zelenetz designed research; B. D. Cheson edited the paper; and G. P. Canellos designed research and edited the paper.

Received for publication September 11, 2006. Revision received February 12, 2007. Accepted for publication February 13, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

in this issue

Ann Oncol 2007 18: 967. [Extract] [Full Text]  



This article has been cited by other articles:


Home page
 Ann OncolHome page
J. H. Mendler, J. Kelly, S. Voci, D. Marquis, L. Rich, R. M. Rossi, S. H. Bernstein, C. T. Jordan, J. Liesveld, R. I. Fisher, et al.
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma
Ann. Onc., May 25, 2008; (2008) mdn365v1.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.